Article
Environmental Sciences
Mingcong Chen, Yang Yang, Krishna Baral, Yicheng Fu, Yang Meng, Yang Zhang, Fang Sun, Mingyi Zhao
Summary: This study analyzed the relationship between bisphenol A (BPA) concentrations and metabolic risk factors for cardiovascular diseases (CVDs) using population-based data. The results showed that higher BPA concentrations were associated with increased metabolic risk for CVDs. Therefore, further regulation of BPA may be necessary for the prevention of CVDs in adults.
Article
Immunology
Anton V. Tyurin, Milyausha K. Salimgareeva, Ildar R. Miniakhmetov, Rita I. Khusainova, Alexandr Samorodov, Valentin N. Pavlov, Julia Kzhyshkowska
Summary: The immune system is severely compromised in patients with COVID-19, showing correlations with inflammation levels and subsets of immune cells. Additionally, deficiencies in the adaptive immune system are correlated with deficiencies in iron metabolism.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Amy T. Peters, Caitlin E. Millett, Jessica Harder, Julia Potter, Raina Fichorova, Andrew A. Nierenberg, Katherine E. Burdick
Summary: The study revealed a correlation between peripheral inflammation and reduced negative target discriminability, as well as faster response times in individuals with bipolar disorder. This suggests that inflammation may be implicated in cognitive-affective processing, warranting further research.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Hartej Gill, Nelson B. Rodrigues, Rodrigo B. Mansur, CeAnn A. Marks, Joshua D. DiVincenzo, Felicia Ceban, Joshua D. Rosenblat, Bing Cao, Jonathan M. Lieberman, Roger Ho, Roger S. McIntyre
Summary: This study aimed to evaluate the antidepressant effects of adjunctive infliximab treatment in BD patients and understand its impact on cardiovascular disease (CVD) risk. The results showed no significant differences between the infliximab-treated and placebo group in terms of Framingham risk scores (FRS), mean arterial blood pressure (MAP), and total cholesterol (TC). This suggests that immune system targets have complex effects on CVD in psychiatric populations.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Endocrinology & Metabolism
Joao Leonardo Silveira Rossi, Sandra Maria Barbalho, Renan Reverete de Araujo, Marcelo Dib Bechara, Katia Portero Sloan, Lance Alan Sloan
Summary: Metabolic syndrome is a chronic syndrome characterized by insulin resistance, hypertension, abdominal obesity, impaired glucose metabolism, and dyslipidemia. These risk factors are closely related to inflammation, oxidative stress, and cardiovascular diseases.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2022)
Article
Multidisciplinary Sciences
Nigist Alemayehu Woldekidan, Ammas Siraj Mohammed, Amsalu Degu, Yohannes Tadiwos
Summary: The majority of psychiatric patients studied were at risk of metabolic syndrome, with sex, marital status, employment status, and distance to the hospital being significantly associated with this risk. Routine screening for metabolic syndrome is crucial in psychiatric patients to prevent cardiovascular complications.
Article
Nutrition & Dietetics
Kun Xue, Yuwei Liu, Kia Nohr Iversen, Mohsen Mazidi, Zheng Qu, Chenglin Dong, Tayi Jin, Goran Hallmans, Per Aman, Anders Johansson, Gengsheng He, Rikard Landberg
Summary: The study compared the effects of high-fiber wholegrain rye foods with added fermented rye bran versus refined wheat on Helicobacter pylori infection and cardiometabolic risk markers in a Chinese population. While no difference was found in Helicobacter pylori bacterial load, the high-fiber rye foods significantly lowered LDL-C and hs-CRP levels compared to refined wheat, suggesting a potential strategy for primary prevention of cardiovascular disease.
FRONTIERS IN NUTRITION
(2021)
Article
Psychiatry
Alessandro Cuomo, Despoina Koukouna, Alessandro Spiti, Giovanni Barilla, Arianna Goracci, Simone Bolognesi, Andrea Fagiolini
Summary: This pilot study evaluated the relationship between C-Reactive-Protein (CRP) and bipolar disorder severity in 61 hospitalized patients. It found a statistically significant decrease in CRP values after 7 days of hospitalization, with positive correlations between CRP and CGI scores at baseline and after 7 days.
FRONTIERS IN PSYCHIATRY
(2021)
Review
Biochemistry & Molecular Biology
Mihaela-Andreea Podeanu, Adina Turcu-Stiolica, Mihaela Simona Subtirelu, Mioara Desdemona Stepan, Claudiu-Marinel Ionele, Dan-Ionut Gheonea, Bianca Stefanita Vintilescu, Raluca Elena Sandu
Summary: The study suggests that C-reactive protein (CRP) is a reliable marker for detecting inflammation in pediatric patients with metabolic syndrome (MetS). However, it may not be very accurate in distinguishing between patients with MetS and those who are obese.
Article
Clinical Neurology
Suyi Shao, Yi Zou, Kody G. Kennedy, Mikaela K. Dimick, Bradley J. Macintosh, Benjamin Goldstein
Summary: This study found that higher C-reactive protein (CRP) levels are associated with increased cortical surface area (SA) but decreased cortical thickness in youth with bipolar disorder. The study also identified two regions where the association between CRP and brain structure differs between youth with bipolar disorder and the control group.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Geriatrics & Gerontology
Sandra Abou Kassm, Marina Sanchez Rico, Wadih Naja, Jesus M. Alvarado, Athar Halaby, Frederic Limosin, Nicolas Hoertel
Summary: No study has explored the association of individual components of metabolic syndrome with mortality in older patients with psychiatric disorders. In this report, the researchers examined whether metabolic syndrome or any of its components predicted mortality in a cohort of older adults with psychiatric disorders. The study found that metabolic syndrome was significantly associated with increased all-cause and disease-related mortality in older adults with major depressive disorder.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2022)
Article
Biochemistry & Molecular Biology
Anna Bartosiewicz, Edyta Luszczki, Malgorzata Nagorska, Lukasz Oleksy, Artur Stolarczyk, Katarzyna Deren
Summary: Metabolic syndrome is prevalent among nurses in Poland, with overweight and obesity being significant factors influencing its development. Preventive and supportive measures are necessary to address this issue.
Article
Clinical Neurology
Maya Kuperberg, Ole Kohler-Forsberg, Alec P. Shannon, Nevita George, Sophie Greenebaum, Charles L. Bowden, Joseph R. Calabrese, Michael Thase, Richard C. Shelton, Melvin McInnis, Thilo Deckersbach, Mauricio Tohen, James H. Kocsis, Terence A. Ketter, Edward S. Friedman, Dan Iosifescu, Michael J. Ostacher, Louisa G. Sylvia, Susan L. McElroy, Andrew A. Nierenberg
Summary: The study found that patients with bipolar disorder have an increased cardiometabolic risk associated with symptom severity, and treatment with quetiapine can worsen cardiometabolic markers. The results highlight the importance of monitoring cardiometabolic risks during treatment.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
R. Queissner, M. Lenger, A. Birner, N. Dalkner, F. Fellendorf, S. Bengesser, M. Platzer, C. Hamm, A. Maget, B. Reininghaus, M. Ratzenhofer, J. Schuller, H. Mangge, H. P. Kapfhammer, E. Z. Reininghaus
Summary: The study found a significant association between symptom progression, duration of lithium treatment, and hsCRP levels in male BD patients. Longer duration of lithium treatment was negatively correlated with hsCRP levels, suggesting a potential anti-inflammatory effect of lithium.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Psychiatry
Daniela Caldirola, Silvia Dacco, Francesco Cuniberti, Massimiliano Grassi, Simona Lorusso, Giuseppina Diaferia, Giampaolo Perna
Summary: This study compared eCRP levels in patients with MDD, BD, and OCD, suggesting that eCRP may be a common feature of different psychiatric disorders. Beyond multiple confounders, other mechanisms may explain the presence of eCRP in a substantial portion of psychiatric patients.
JOURNAL OF PSYCHOSOMATIC RESEARCH
(2021)
Article
Psychiatry
Liliana Gomez Cardona, Kristyn Brown, Taylor Goodleaf, Mary McComber, Rebecca D'Amico, Allyson Phillips, Cyndy Boyer, Codey Martin, Brooke Splicer, Suzy Goodleaf, Darrell Thompson, Melissa Haswell, Arlene Laliberte, Outi Linnaranta
Summary: The study culturally adapted the Growth and Empowerment Measure for the Kanien'keha:ka people of Quebec, using a qualitative, collaborative, and participatory approach. Through focus group meetings and data analysis, socioculturally relevant elements were integrated to create a versatile assessment tool reflecting local well-being factors.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lara E. Murphy, Trehani M. Fonseka, Chad A. Bousman, Daniel J. Mueller
Summary: There are significant individual differences in the therapeutic effectiveness and adverse effects of antidepressant and antipsychotic medications, which can be partially explained by genetic variation. Evidence-based guidelines are available for pharmacogenetic-guided prescribing of these medications, but key barriers such as economic, educational, regulatory, and ethical issues need to be addressed for optimal patient care outcomes.
MOLECULAR PSYCHIATRY
(2022)
Review
Neurosciences
Eunsoo Moon, Timo Partonen, Serge Beaulieu, Outi Linnaranta
Summary: This systematic review and meta-analysis examines the effects of melatonin supplements and agonists on sleep-wake cycle and melatonin circadian rhythm. It found that these agents can advance the sleep-wake cycle in both healthy participants and patients with psychiatric disorders, indicating their potential value in regulating circadian rhythms.
NEUROPSYCHOPHARMACOLOGY
(2022)
Correction
Pharmacology & Pharmacy
Jose de Leon, Georgios Schoretsanitis, Robert L. Smith, Espen Molden, Anssi Solismaa, Niko Seppala, Miloslav Kopecek, Patrik Svancer, Ismael Olmos, Carina Ricciardi, Celso Iglesias-Garcia, Ana Iglesias-Alonso, Edoardo Spina, Can-Jun Ruan, Chuan-Yue Wang, Gang Wang, Yi-Lang Tang, Shih-Ku Lin, Hsien-Yuan Lane, Yong Sik Kim, Se Hyun Kim, Anto P. Rajkumar, Dinora F. Gonzalez-Esquivel, Helgi Jung-Cook, Trino Baptista, Christopher Rohde, Jimmi Nielsen, Helene Verdoux, Clelia Quiles, Emilio J. Sanz, Carlos De las Cuevas, Dan Cohen, Peter F. J. Schulte, Aygun Ertugrul, Nitin Chopra, Betsy McCollum, Charles Shelton, Robert O. Cotes, Arun R. Kaithi, John M. Kane, Saeed Farooq, Chee H. Ng, John Bilbily, Christoph Hiemke, Carlos Lopez-Jaramillo, Ian McGrane, Fernando Lana, Chin B. Eap, Manuel Arrojo-Romero, Erich Seifritz, Susanna Every-Palmer, Chad A. Bousman, Emmanuel Bebawi, Rahul Bhattacharya, Deanna L. Kelly, Yuji Otsuka, Judit Lazary, Rafael Torres, Agustin Yecora, Mariano Motuca, Sherry K. W. Chan, Monica Zolezzi, Sami Ouanes, Domenico De Berardis, Sandeep Grover, Ric M. Procyshyn, Richard A. Adebayo, Oleg O. Kirilochev, Andrey Soloviev, Konstantinos N. Fountoulakis, Alina Wilkowska, Muhammad Ayub, Alzira Silva, Raphael M. Bonelli, Jose M. Villagran-Moreno, Benedicto Crespo-Facorro, Henk Temmingh, Eric Decloedt, Maria R. Pedro, Hiroyoshi Takeuchi, Masaru Tsukahara, Gerhard Gruender, Marina Sagud, Andreja Celofiga, Dragana Ignjatovic Ristic, Bruno B. Ortiz, Helio Elkis, Antonio J. Pacheco Palha, Adrian LLerena, Emilio Fernandez-Egea, Dan Siskind, Abraham Weizman, Rim Masmoudi, Shamin Mohd Saffian, Jonathan G. Leung, Peter F. Buckley, Stephen R. Marder, Leslie Citrome, Oliver Freudenreich, Christoph U. Correll, Daniel J. Muller, A. Elif Anil Yagcioglu, Flavian S. Radulescu, Wieslaw J. Cubala
PHARMACOPSYCHIATRY
(2022)
Review
Pharmacology & Pharmacy
Jose de Leon, Georgios Schoretsanitis, Robert L. Smith, Espen Molden, Anssi Solismaa, Niko Seppala, Miloslav Kopecek, Patrik Svancer, Ismael Olmos, Carina Ricciardi, Celso Iglesias-Garcia, Ana Iglesias-Alonso, Edoardo Spina, Can-Jun Ruan, Chuan-Yue Wang, Gang Wang, Yi-Lang Tang, Shih-Ku Lin, Hsien-Yuan Lane, Yong Sik Kim, Se Hyun Kim, Anto P. Rajkumar, Dinora F. Gonzalez-Esquivel, Helgi Jung-Cook, Trino Baptista, Christopher Rohde, Jimmi Nielsen, Helene Verdoux, Clelia Quiles, Emilio J. Sanz, Carlos De las Cuevas, Dan Cohen, Peter F. J. Schulte, Aygun Ertugrul, Nitin Chopra, Betsy McCollum, Charles Shelton, Robert O. Cotes, Arun R. Kaithi, John M. Kane, Saeed Farooq, Chee H. Ng, John Bilbily, Christoph Hiemke, Carlos Lopez-Jaramillo, Ian McGrane, Fernando Lana, Chin B. Eap, Manuel Arrojo-Romero, Erich Seifritz, Susanna Every-Palmer, Chad A. Bousman, Emmanuel Bebawi, Rahul Bhattacharya, Deanna L. Kelly, Yuji Otsuka, Judit Lazary, Rafael Torres, Agustin Yecora, Mariano Motuca, Sherry K. W. Chan, Monica Zolezzi, Sami Ouanes, Domenico De Berardis, Sandeep Grover, Ric M. Procyshyn, Richard A. Adebayo, Oleg O. Kirilochev, Andrey Soloviev, Konstantinos N. Fountoulakis, Alina Wilkowska, Muhammad Ayub, Alzira Silva, Raphael M. Bonelli, Jose M. Villagran-Moreno, Benedicto Crespo-Facorro, Henk Temmingh, Eric Decloedt, Maria R. Pedro, Hiroyoshi Takeuchi, Masaru Tsukahara, Gerhard Gruender, Marina Sagud, Andreja Celofiga, Dragana Ignjatovic Ristic, Bruno B. Ortiz, Helio Elkis, Antonio J. Pacheco Palha, Adrian LLerena, Emilio Fernandez-Egea, Dan Siskind, Abraham Weizman, Rim Masmoudi, Shamin Mohd Saffian, Jonathan G. Leung, Peter F. Buckley, Stephen R. Marder, Leslie Citrome, Oliver Freudenreich, Christoph U. Correll, Daniel J. Muller, A. Elif Anil Yagcioglu, Flavian S. Radulescu, Wieslaw J. Cubala
Summary: This international guideline suggests improving clozapine package inserts globally by utilizing ancestry-based dosing and gradual titration to prevent potential toxicity and ADRs. It defines six personalized titration schedules for different populations and recommends monitoring inflammation globally.
PHARMACOPSYCHIATRY
(2022)
Article
Psychiatry
Anthony L. Vaccarino, Derek Beaton, Sandra E. Black, Pierre Blier, Farnak Farzan, Elizabeth Finger, Jane A. Foster, Morris Freedman, Benicio N. Frey, Susan Gilbert Evans, Keith Ho, Mojib Javadi, Sidney H. Kennedy, Raymond W. Lam, Anthony E. Lang, Bianca Lasalandra, Sara Latour, Mario Masellis, Roumen V. Milev, Daniel J. Mueller, Douglas P. Munoz, Sagar V. Parikh, Franca Placenza, Susan Rotzinger, Claudio N. Soares, Alana Sparks, Stephen C. Strother, Richard H. Swartz, Brian Tan, Maria Carmela Tartaglia, Valerie H. Taylor, Elizabeth Theriault, Gustavo Turecki, Rudolf Uher, Lorne Zinman, Kenneth R. Evans
Summary: Brain-CODE is an informatics platform that collects, stores, and integrates data to understand the causes of brain dysfunction and develop new treatment approaches. By providing access to diverse datasets, including clinical, neuroimaging, and molecular data, Brain-CODE facilitates analyses within and across brain disorders. The establishment of Common Data Elements ensures consistency in data collection and enhances the ability to analyze pooled participant-level data.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Neurosciences
Prabhjot Dhami, Lena C. Quilty, Benjamin Schwartzmann, Rudolf Uher, Timothy A. Allen, Stefan Kloiber, Raymond W. Lam, Glenda MacQueen, Benicio N. Frey, Roumen Milev, Daniel J. Mueller, Stephen C. Strother, Pierre Blier, Claudio N. Soares, Sagar V. Parikh, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Faranak Farzan
Summary: The neurobiological correlates of response inhibition can predict the response of patients with major depressive disorder (MDD) to pharmacological and cognitive behavioral therapy treatment. The integrity of response inhibition may be crucial for the success of treatment for MDD. Electrophysiological correlates of response inhibition may serve as a general prognostic marker for treatment response in MDD.
BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING
(2023)
Review
Biochemistry & Molecular Biology
Sauliha R. Alli, Ilona Gorbovskaya, Jonathan C. W. Liu, Nathan J. Kolla, Lisa Brown, Daniel J. Muller
Summary: A growing body of research indicates differences in the gut microbiome of major depressive disorder (MDD) patients compared to healthy controls. Prebiotic, probiotic, and synbiotic treatments show modest benefit in reducing depressive symptoms. However, further studies are needed before these therapies can be implemented in clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, Sakiko Tsugawa, Kazunari Yoshida, Hideaki Tani, Yoji Hirano, Shinsuke Koike, Daiki Sasabayashi, Haruyuki Katayama, Eric Plitman, Kazutaka Ohi, Fumihiko Ueno, Fernando Caravaggio, Teruki Koizumi, Philip Gerretsen, Takefumi Suzuki, Hiroyuki Uchida, Daniel J. Muller, Masaru Mimura, Gary Remington, Anthony A. Grace, Ariel Graff-Guerrero, Shinichiro Nakajima
Summary: This review discusses potential treatments for treatment-resistant schizophrenia, focusing on the therapeutic potential of neuromodulation. It also proposes a multivariate analysis approach that integrates various pathophysiological perspectives, providing a roadmap for future research in this area.
MOLECULAR PSYCHIATRY
(2022)
Correction
Psychiatry
Arun K. Tiwari, Clement C. Zai, C. Anthony Altar, Julie-Anne Tanner, Paige E. Davies, Paul Traxler, James Li, Elizabeth S. Cogan, Matthew T. Kucera, Ana Gugila, Nicole Braganza, Heather Emmerson, Gwyneth Zai, Daniel J. Muller, Robert Levitan, Stefan Kloiber, Zafiris J. Daskalakis, Benicio N. Frey, James M. Bowen, Jean-Eric Tarride, Richard Tytus, Ranjith Chandrasena, Nicholas Voudouris, Valerie H. Taylor, Raymond Tempier, Verinder Sharma, Akshya Vasudev, Peter Dzongowski, Lew Pliamm, Todd Greenspoon, Bryan M. Dechairo, James L. Kennedy
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Psychiatry
Arun K. Tiwari, Clement C. Zai, C. Anthony Altar, Julie-Anne Tanner, Paige E. Davies, Paul Traxler, James Li, Elizabeth S. Cogan, Matthew T. Kucera, Ana Gugila, Nicole Braganza, Heather Emmerson, Gwyneth Zai, Daniel J. Muller, Robert Levitan, Stefan Kloiber, Zafiris J. Daskalakis, Benicio N. Frey, James M. Bowen, Jean-Eric Tarride, Richard Tytus, Ranjith Chandrasena, Nicholas Voudouris, Valerie H. Taylor, Raymond Tempier, Verinder Sharma, Akshya Vasudev, Peter Dzongowski, Lew Pliamm, Todd Greenspoon, Bryan M. Dechairo, James L. Kennedy
Summary: The pharmacological treatment of depression involves trial and error, with a low remission rate during the first medication trial. However, a study showed that patients who received treatment guided by combinatorial pharmacogenomic testing had significant improvements in response and remission rates.
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Behavioral Sciences
Caroline W. Espinola, Yuelee Khoo, Roohie Parmar, Ilya Demchenko, Benicio N. Frey, Roumen Milev, Arun Ravindran, Sagar Parikh, Keith Ho, Susan Rotzinger, Wendy Lou, Raymond W. Lam, Sidney H. Kennedy, Venkat Bhat
Summary: This study aimed to report the frequency and severity of side effects in patients with major depressive disorder (MDD) receiving adjunctive therapy of escitalopram and aripiprazole, and to examine the association between pretreatment anxious depression and the number and presence of specific side effects. The results demonstrated that the most frequent and severe side effects were related to the central nervous system. Furthermore, patients with anxious depression were more likely to experience side effects, especially those related to anxiety, when receiving escitalopram treatment.
BRAIN AND BEHAVIOR
(2022)
Article
Psychology, Clinical
Mehri Sajjadian, Rudolf Uher, Keith Ho, Stefanie Hassel, Roumen Milev, Benicio N. Frey, Faranak Farzan, Pierre Blier, Jane A. Foster, Sagar Parikh, Daniel J. Mueller, Susan Rotzinger, Claudio N. Soares, Gustavo Turecki, Valerie H. Taylor, Raymond W. Lam, Stephen C. Strother, Sidney H. Kennedy
Summary: Predicting treatment outcomes for major depressive disorder can be improved by combining clinical, neuroimaging, and molecular data. Early measurement during treatment can increase precision, but adding more features does not necessarily enhance prediction accuracy.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Health Care Sciences & Services
Quinta Seon, Noor Mady, Michelle Yang, Maharshee Karia, Myrna Lashley, Claudia Sescu, Maud Lalonde, Stephen Puskas, Joy Outerbridge, Echo Parent-Racine, Catherine Pagiatakis, Liliana Gomez-Cardona, Di Jiang, Stephane Bouchard, Outi Linnaranta
Summary: This study presents a protocol for a culturally adapted virtual reality cognitive behavioral therapy trial among Inuit in Quebec. The research aims to investigate the feasibility, benefits, and challenges of the culturally adapted intervention compared to a commercial self-management program, as well as examine self-rated mental well-being and objective psychophysiological measures. The study's importance lies in meeting the need for accessible and appropriate psychological well-being resources for Inuit, incorporating novel technology and measurement methods, and providing evidence for culturally adapted RCTs.
JMIR RESEARCH PROTOCOLS
(2023)
Review
Psychiatry
Michelle Yang, Quinta Seon, Liliana Gomez Cardona, Maharshee Karia, Gajanan Velupillai, Valerie Noel, Outi Linnaranta
Summary: Implementing culturally sensitive psychometric measures of depression can improve acceptance and reliability. However, the psychometric properties of culturally adapted depression scales remain unclear, with some improvements in cultural sensitivity but potential decreases in specificity and negative predictive value.
CAMBRIDGE PRISMS-GLOBAL MENTAL HEALTH
(2023)
Article
Clinical Neurology
Nadia Deflorin, Ulrike Ehlert, Rita T. Amiel Castro
Summary: Changes in the gut microbiome of infants have been associated with maternal psychological symptoms during pregnancy. This study found that maternal prenatal depressive symptoms are associated with lower diversity of the infant's microbiome, while maternal saliva cortisol levels are linked to increased diversity and changes in specific bacterial groups. Further research is needed to understand the implications of these microbiota alterations for child health.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Zheng Ma, Hui-Xia Zhou, Da-Chun Chen, Dong-Mei Wang, Xiang-Yang Zhang
Summary: The impaired glucose metabolism in drug-na & iuml;ve schizophrenia patients is strongly associated with suicidal behavior, suggesting that glucose metabolism abnormalities may be potential biomarkers of suicide in schizophrenia patients. Regular monitoring of glucose metabolism variables is essential for suicide prevention.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Katie M. Lavigne, Jiaxuan Deng, Delphine Raucher-Chene, Adele Hotte-Meunier, Chloe Voyer, Lisa Sarraf, Martin Lepage, Genevieve Sauve
Summary: Psychiatric disorders are characterized by cognitive deficits and cognitive biases, which are associated with specific symptoms. While cognitive biases are present across diagnoses, their severity varies.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Yong-Yu Yin, Jiao-Zhao Yan, Shi-Xin Lai, Qian-Qian Wei, Si-Rui Sun, Li-Ming Zhang, Yun-Feng Li
Summary: This study found that gamma oscillations are closely associated with depression and may serve as predictive biomarkers of depression. Chronic restraint stress and lipopolysaccharide induced significant depression-like behaviors in mice and reduced gamma oscillations in the medial prefrontal cortex. Administration of ketamine, scopolamine, or fluoxetine increased gamma oscillations and exhibited rapid-acting antidepressant effects.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Veronica Begni, Moira Marizzoni, Kerstin Camile Creutzberg, Diana Morena Silipo, Mariusz Papp, Annamaria Cattaneo, Marco Andrea Riva
Summary: Exposure to stressful experiences is a significant risk factor for mental disorders, and pharmacological interventions targeting stress-induced alterations can help restore brain function. Lurasidone, an antipsychotic drug, has been shown to normalize the impairments caused by stress exposure and could be a valuable treatment for stress-induced mental illnesses. However, the mechanisms underlying the therapeutic effects of lurasidone are not well understood. This study found that chronic lurasidone treatment counteracted some of the transcriptional changes induced by chronic mild stress exposure, providing new insights into the potential therapeutic effects of lurasidone.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Esther E. Palacios-Barrios, Kunal Patel, Jamie L. Hanson
Summary: This review examines the association between early life interpersonal stress (ELIS) and depression, as well as the underlying mechanisms. The research shows that ELIS affects how youth respond to social rewards, and similar impairments in social reward processing are observed in youth with depression. The authors propose a preliminary model that suggests neurobehavioral disruptions in social reward processing as a mediating factor in the connection between ELIS and depression.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Rui Li, Jiaming Tang, Yizhuo Wang, Ying Wang, Hua Yang, Hongen Wei
Summary: Restricted and repetitive behaviors (RRBs) are characteristic features of neuropsychiatric disorders. This study focused on repetitive self-grooming behavior and investigated the involvement of the Pax2 gene in its control. Through the use of Pax2 neuron-specific deletion mice, the study found that the deletion of Pax2 gene affects the expression of the Arc gene in the prefrontal cortex, leading to impaired synaptic plasticity and excitatory/inhibitory imbalance, thereby contributing to the occurrence of repetitive self-grooming behavior.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Sara Derosa, Paulina Misztak, Jessica Mingardi, Giulia Mazzini, Heidi Kaastrup Muller, Laura Musazzi
Summary: This study investigated the involvement of neurotrophic signaling pathways in stress vulnerability/resilience and fast antidepressant response/non-response to ketamine in a rat model of depression. The findings showed that stress and ketamine induced specific changes in these pathways in different brain areas and subcellular fractions.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Review
Clinical Neurology
Georgia F. Caruana, Sean P. Carruthers, Michael Berk, Susan L. Rossell, Tamsyn E. Van Rheenen
Summary: Cognitive impairment is related to both white matter macrostructure and microstructure in bipolar disorder patients. However, there is inconsistency in the results of the studies examining this relationship. Some studies have found an association between higher fractional anisotropy in white matter and better complex attention skills and executive functioning in bipolar disorder patients, while others have found no associations. Further research with increased statistical power and standardized methods is needed.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Review
Clinical Neurology
Alberto Galimberti, Martin Tik, Giovanni Pellegrino, Anna-Lisa Schuler
Summary: This study provides a systematic review and meta-analysis on the effectiveness of repetitive transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) for post-traumatic brain injury (TBI) symptoms. The results show that non-invasive brain stimulation techniques have a small overall effect on TBI sequelae, with significant effects observed for anxiety and headache. However, larger randomized controlled trials with longer follow-ups, optimized stimulation parameters, and standardized methodology are needed to establish the efficacy of these techniques in addressing TBI sequelae.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Amanda J. Sales, Pedro H. Gobira, Joa F. C. Pedrazzi, Joao R. Silveia, Elaine Del Bel, Felipe V. Gomes, Francisco S. Guimaraes
Summary: The study found that doxycycline can inhibit metalloproteinase in the brain and attenuate the rewarding effects and locomotor sensitization of drug abuse. This suggests that doxycycline could be repurposed for the treatment of substance use disorders.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Alejandro Borrego-Ruiz, Juan J. Borrego
Summary: There is substantial evidence that the development of the nervous system is related to the composition and functions of the gut microbiome. The communication between the central nervous system (CNS) and the gut microbiota is bidirectional, with various routes such as immune, endocrine, and neural circuits. Dysbiosis of the gut microbiota has been associated with neuropsychiatric diseases and psychological disorders. Fecal microbiota transplantation (FMT) therapy has shown a causal-effect relationship between the gut microbiota and behavioral features. Interventions based on prebiotics, probiotics, or synbiotics have demonstrated their influence on neurological disorders through the synthesis of neuroactive compounds and regulation of inflammatory and endocrine processes. Further research is needed to explore the impact of gut microbiota dysbiosis on psychiatric and psychological disorders and the potential therapeutic role of microbiota-based interventions.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Zhinan Li, Zhuang Kang, Xiaowei Xia, Leijun Li, Junyan Wu, Jiamin Dai, Tong Liu, Cai Chen, Yong Qiu, Ming Chen, Yanxi Liu, Ziyi Zhang, Zili Han, Zhengjia Dai, Qinling Wei
Summary: This study found that patients with schizophrenia showed lower levels of resilience and cognitive functions compared to healthy controls, as well as abnormal global properties and nodal metrics in brain networks. Furthermore, characteristic path length might moderate the relationship between resilience and working memory in these patients.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
David H. Adamowicz, Tsung-Chin Wu, Rebecca Daly, Michael R. Irwin, Dilip Jeste, Xin M. Tu, Lisa T. Eyler, Ellen E. Lee
Summary: This study aimed to explore the relationship between executive functioning and inflammatory biomarkers in people with schizophrenia. The results showed that systemic inflammation did not predict long-term declines in executive functioning. This suggests the need for further research to better understand the relationship and mechanisms between inflammation and cognition in schizophrenia.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Article
Clinical Neurology
Nina Walter, Julian Wenzel, Shalaila S. Haas, Letizia Squarcina, Carolina Bonivento, Anne Ruef, Dominic Dwyer, Theresa Lichtenstein, Oeznur Bastruek, Alexandra Stainton, Linda A. Antonucci, Paolo Brambilla, Stephen J. Wood, Rachel Upthegrove, Stefan Borgwardt, Rebekka Lencer, Eva Meisenzahl, Raimo K. R. Salokangas, Christos Pantelis, Alessandro Bertolino, Nikolaos Koutsouleris, Joseph Kambeitz, Lana Kambeitz-Ilankovic
Summary: Clinical and neuroimaging data can be used to predict the potential of cognitive training to improve social functioning in recent onset psychosis patients. The use of multivariate pattern analysis and support vector machine classifier allows for the prediction of social functioning improvement based on baseline cognitive data. The findings suggest that cognitive data can provide a robust individual estimate of future social functioning for patients with recent onset psychosis.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)